|
|
Volumn 26, Issue 11, 2008, Pages 1900-1901
|
|
Could the efficacy of docetaxel in prostate cancer patients be potentiated by concomitant high-dose calcitriol administration?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CALCITRIOL;
DOCETAXEL;
PARATHYROID HORMONE;
PLACEBO;
ZOLEDRONIC ACID;
ANTINEOPLASTIC AGENT;
BONE DENSITY CONSERVATION AGENT;
TAXOID;
ANTINEOPLASTIC ACTIVITY;
BONE METASTASIS;
CANCER RISK;
CANCER SURVIVAL;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
DRUG EFFICACY;
DRUG FATALITY;
DRUG MEGADOSE;
HUMAN;
HYPERPARATHYROIDISM;
HYPOCALCEMIA;
LETTER;
MONOTHERAPY;
PARATHYROID HORMONE BLOOD LEVEL;
PRIORITY JOURNAL;
PROSTATE CANCER;
VITAMIN DEFICIENCY;
BONE TUMOR;
DRUG POTENTIATION;
MALE;
METASTASIS;
NOTE;
PROSTATE TUMOR;
ANTINEOPLASTIC AGENTS;
BONE DENSITY CONSERVATION AGENTS;
BONE NEOPLASMS;
CALCITRIOL;
CLINICAL TRIALS AS TOPIC;
DRUG SYNERGISM;
HUMANS;
HYPOCALCEMIA;
MALE;
PROSTATIC NEOPLASMS;
TAXOIDS;
|
|
EID: 42949095358
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2007.15.7941 Document Type: Letter |
|
Times cited : (3)
|
|
References (6)
|
